Prostaglandin receptors are mediators of vascular function in endometrial pathologies

Molecular and Cellular Endocrinology

Volumn 252, Issue 1-2, 2006, Pages 191-200

  Jabbour, Henry N ^a   Sales, Kurt J ^a   Smith, Oliver P Milling ^a   Battersby, Sharon ^a   Boddy, Sheila C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiogenesis; Endometrium; Prostaglandin receptors; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROSTANOID RECEPTOR;

ARTICLE; BENIGN TUMOR; BLOOD VESSEL FUNCTION; DYSMENORRHEA; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; HUMAN; NEOPLASM; PRIORITY JOURNAL; SEMINAL PLASMA;

ANIMALS; BLOOD VESSELS; DYSMENORRHEA; ELECTRON TRANSPORT COMPLEX IV; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; MENORRHAGIA; MENSTRUAL CYCLE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN;

EID: 33745185130     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.03.025     Document Type: Article

References (119)

1. Abberton K.M., Taylor N.H., Healy D.L., and Rogers P.A. Vascular smooth muscle alpha-actin distribution around endometrial arterioles during the menstrual cycle: increased expression during the perimenopause and lack of correlation with menorrhagia. Hum. Reprod. 11 (1996) 204-211
2. Abberton K.M., Taylor N.H., Healy D.L., and Rogers P.A. Vascular smooth muscle cell proliferation in arterioles of the human endometrium. Hum. Reprod. 14 (1999) 1072-1079
3. Adelantado J.M., Rees M.C., Lopez Bernal A., and Turnbull A.C. Increased uterine prostaglandin E receptors in menorrhagic women. Br. J. Obstet. Gynaecol. 95 (1988) 162-165
4. Anderson A.B., Haynes P.J., Guillebaud J., and Turnbull A.C. Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors. Lancet 1 (1976) 774-776
5. Bartosik D., Jacobs S.L., and Kelly L.J. Endometrial tissue in peritoneal fluid. Fert. Steril. 46 (1986) 796-800
6. Battersby S., Critchley H.O., Morgan K., Millar R.P., and Jabbour H.N. Expression and regulation of the prokineticins (endocrine gland-derived vascular endothelial growth factor and Bv8) and their receptors in the human endometrium across the menstrual cycle. J. Clin. Endocrinol. Metab. 89 (2004) 2463-2469
7. Bley K.R., Hunter J.C., Eglen R.M., and Smith J.A. The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol. Sci. 19 (1998) 141-147
8. Blumenthal R.D., Taylor A.P., Goldman L., Brown G., and Goldenberg D.M. Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometrium. Fert. Steril. 78 (2002) 1294-1300
9. Brenner R.M., Nayak N.R., Slayden O.D., Critchley H.O., and Kelly R.W. Premenstrual and menstrual changes in the macaque and human endometrium: relevance to endometriosis. Ann. NY Acad. Sci. 955 (2002) 60-74
10. Brosens J.J., Mak I., and Brosens M.I. Mechanisms of dysmenorrhoea. In: O'Brien S., Cameron I., and MacLean A. (Eds). Disorders of the Menstrual Cycle (2000), RCOG Press, London 113-132
11. Buttram Jr. V.C., and Reiter R.C. Uterine leiomyomata: etiology, symptomatology, and management. Fert. Steril. 36 (1981) 433-445
12. Cameron I.T. Dysfunctional uterine bleeding. Baillieres Clin. Obstet. Gynaecol. 3 (1989) 315-327
13. Cameron I.T., Haining R., Lumsden M.A., Thomas V.R., and Smith S.K. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet. Gynecol. 76 (1990) 85-88
14. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., and Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13926-13931
15. Chiazze Jr. L., Brayer F.T., Macisco Jr. J.J., Parker M.P., and Duffy B.J. The length and variability of the human menstrual cycle. JAMA 203 (1968) 377-380
16. Chimbira T.H., Anderson A.B., and Turnbull A. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br. J. Obstet. Gynaecol. 87 (1980) 603-609
17. Chu T.M., Nocera M.A., Flanders K.C., and Kawinski E. Localization of seminal plasma transforming growth factor-beta1 on human spermatozoa: an immunocytochemical study. Fert. Steril. 66 (1996) 327-330
18. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Smithies O., and Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60 (2000) 4705-4708
19. Collisson E.A., De A., Suzuki H., Gambhir S.S., and Kolodney M.S. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK Cascade. Cancer Res. 63 (2003) 5669-5673
20. Coulter A., McPherson K., and Vessey M. Do British women undergo too many or too few hysterectomies?. Soc. Sci. Med. 27 (1988) 987-994
21. Critchley H.O., Abberton K.M., Taylor N.H., Healy D.L., and Rogers P.A. Endometrial sex steroid receptor expression in women with menorrhagia. Br. J. Obstet. Gynaecol. 101 (1994) 428-434
22. Critchley H.O., Brenner R.M., Henderson T.A., Williams K., Nayak N.R., Slayden O.D., Millar M.R., and Saunders P.T. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J. Clin. Endocrinol. Metab. 86 (2001) 1370-1378
23. Critchley H.O., Kelly R.W., Brenner R.M., and Baird D.T. The endocrinology of menstruation-a role for the immune system. Clin. Endocrinol. 55 (2001) 701-710
24. Critchley H.O.D., Jones R.L., Lea R.G., Drudy T.A., Kelly R.W., Williams A.R., and Baird D.T. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J. Clin. Endocrinol. Metab. 84 (1999) 240-248
25. Daniels S.E., Talwalker S., Torri S., Snabes M.C., Recker D.P., and Verburg K.M. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet. Gynecol. 100 (2002) 350-358
26. 2 and interleukin-1beta. Endocrinology 140 (1999) 2685-2695
27. Dawood M.Y. Dysmenorrhea. J. Reprod. Med. 30 (1985) 154-167
28. Dinchuk J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covington M.B., Contel N.R., Eng V.M., Collins R.J., and Czerniak P.M. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378 (1995) 406-409
29. Dore M., Cote L.C., Mitchell A., and Sirois J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J. Histochem. Cytochem. 46 (1998) 77-84
30. Eldred J.M., and Thomas E.J. Pituitary and ovarian hormone levels in unexplained menorrhagia. Obstet. Gynecol. 84 (1994) 775-778
31. Ellenson L.H., and Wu T.C. Focus on endometrial and cervical cancer. Cancer Cell 5 (2004) 533-538
32. Ferrandina G., Legge F., Ranelletti F.O., Zannoni G.F., Maggiano N., Evangelisti A., Mancuso S., Scambia G., and Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 95 (2002) 801-807
33. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. 28 (1998) 67-81
34. Fraser I.S. Prostaglandins, prostaglandin inhibitors and their roles in gynaecological disorders. Baillieres Clin. Obstet. Gynaecol. 6 (1992) 829-857
35. Fraser I.S., Pearse C., Shearman R.P., Elliott P.M., McIlveen J., and Markham R. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet. Gynecol. 58 (1981) 543-551
36. 2α stimulation of cyclooxygenase-2 promoter activity by the FPB prostanoid receptor. Eur. J. Pharmacol. 465 (2003) 39-41
37. Gargett C.E., and Rogers P.A. Human endometrial angiogenesis. Reproduction 121 (2001) 181-186
38. Gazvani R., and Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123 (2002) 217-226
39. Gordon M.D., and Ireland K. Pathology of hyperplasia and carcinoma of the endometrium. Semin. Oncol. 21 (1994) 64-70
40. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., and Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
41. Gross G.A., Imamura T., Luedke C., Vogt S.K., Olson L.M., Nelson D.M., Sadovsky Y., and Muglia L.J. Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11875-11879
42. Gutsche S., von Wolff M., Strowitzki T., and Thaler C.J. Seminal plasma induces mRNA expression of IL-1beta, IL-6 and LIF in endometrial epithelial cells in vitro. Mol. Hum. Reprod. 9 (2003) 785-791
43. Hallberg L., Hogdahl A.M., Nilsson L., and Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet. Gynecol. Scand. 45 (1966) 320-351
44. Hewett P., Nijjar S., Shams M., Morgan S., Gupta J., and Ahmed A. Down-regulation of angiopoietin-1 expression in menorrhagia. Am. J. Pathol. 160 (2002) 773-780
45. Hickey M., Dwarte D., and Fraser I.S. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum. Reprod. 15 (2000) 1509-1514
46. Hizaki H., Segi E., Sugimoto Y., Hirose M., Saji T., Ushikubi F., Matsuoka T., Noda Y., Tanaka T., Yoshida N., Narumiya S., and Ichikawa A. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10501-10506
47. Hwang D., Scollard D., Byrne J., and Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90 (1998) 455-460
48. 2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br. J. Cancer 85 (2001) 1023-1031
49. Jones R.L., Kelly R.W., and Critchley H.O.D. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum. Reprod. 12 (1997) 1300-1306
50. Kang J., Chapdelaine P., Parent J., Madore E., Laberge P.Y., and Fortier M.A. Expression of human prostaglandin transporter in the human endometrium across the menstrual cycle. J. Clin. Endocrinol. Metab. 90 (2005) 2308-2313
51. 2α release by human peritoneal macrophages in endometriosis. Prostaglandins 51 (1996) 49-60
52. Kedar D., Baker C.H., Killion J.J., Dinney C.P., and Fidler I.J. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 8 (2002) 3592-3600
53. Kennedy C.R., Zhang Y., Brandon S., Guan Y., Coffee K., Funk C.D., Magnuson M.A., Oates J.A., Breyer M.D., and Breyer R.M. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. 5 (1999) 217-220
54. Kirschenbaum A., Klausner A.P., Lee R., Unger P., Yao S., Liu X., and Levine A.C. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56 (2000) 671-676
55. Kitamura T., Kawamori T., Uchiya N., Itoh M., Noda T., Matsuura M., Sugimura T., and Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 23 (2002) 1463-1466
56. Kooy J., Taylor N.H., Healy D.L., and Rogers P.A. Endothelial cell proliferation in the endometrium of women with menorrhagia and in women following endometrial ablation. Hum. Reprod. 11 (1996) 1067-1072
57. Kouides P.A. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract. Res. Clin. Haematol. 14 (2001) 381-399
58. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 (2001) 429-434
59. Kunz G., Beil D., Deiniger H., Einspanier A., Mall G., and Leyendecker G. The uterine peristaltic pump. Normal and impeded sperm transport within the female genital tract. Adv. Exp. Med. Biol. 424 (1997) 267-277
60. Kunz G., and Leyendecker G. Uterine peristaltic activity during the menstrual cycle: characterization, regulation, function and dysfunction. Reprod. Biomed. Online 4 Suppl. 3 (2002) 5-9
61. Langenbach R., Loftin C., Lee C., and Tiano H. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem. Pharmacol. 58 (1999) 1237-1246
62. Langenbach R., Loftin C.D., Lee C., and Tiano H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. NY Acad. Sci. 889 (1999) 52-61
63. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., and Kluckman K.D. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83 (1995) 483-492
64. Lim H., Paria B.C., Das S.K., Dinchuk J.E., Langenbach R., Trzaskos J.M., and Dey S.K. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91 (1997) 197-208
65. Livingstone M., and Fraser I.S. Mechanisms of abnormal uterine bleeding. Hum. Reprod. Update 8 (2002) 60-67
66. Lockwood C.J., Schatz F., and Krikun G. Angiogenic factors and the endometrium following long term progestin only contraception. Histol. Histopathol. 19 (2004) 167-172
67. 2α. Br. J. Obstet. Gynaecol. 90 (1983) 1135-1140
68. 2 in dysmenorrheic women. Acta Obstet. Gynecol. Scand. 56 (1977) 167-172
69. Lundstrom V. Treatment of primary dysmenorrhea with prostaglandin synthetase inhibitors-a promising therapeutic alternative. Acta Obstet. Gynecol. Scand. 57 (1978) 421-448
70. Lundstrom V., Green K., and Wiqvist N. Prostaglandins, indomethacin and dysmenorrhea. Prostaglandins 11 (1976) 893-907
71. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., and Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
72. Makarainen L., and Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br. J. Obstet. Gynaecol. 93 (1986) 974-978
73. 2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J. Lipid Res. 41 (2000) 873-881
74. Mant J.W., and Vessey M.P. Ovarian and endometrial cancers. Cancer Surv. 20 (1994) 287-307
75. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 68/69 (2002) 165-175
76. Narko K., Ristimaki A., MacPhee M., Smith E., Haudenschild C.C., and Hla T. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J. Biol. Chem. 272 (1997) 21455-21460
77. Narumiya S., and FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108 (2001) 25-30
78. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
79. 2 stimulates aromatase expression in endometriosis-derived stromal cells. J. Clin. Endocrinol. Metab. 82 (1997) 600-606
80. Oral E., Olive D.L., and Arici A. The peritoneal environment in endometriosis. Hum. Reprod. Update 2 (1996) 385-398
81. Ota H., Igarashi S., Sasaki M., and Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum. Reprod. 16 (2001) 561-566
82. Parazzini F., La Vecchia C., Bocciolone L., and Franceschi S. The epidemiology of endometrial cancer. Gynecol. Oncol. 41 (1991) 1-16
83. Perchick G.B., and Jabbour H.N. Cyclooxygenase-2 overexpression inhibits cathepsin D-mediated cleavage of plasminogen to the potent antiangiogenic factor angiostatin. Endocrinology 144 (2003) 5322-5388
84. Pickles V.R., Hall W.J., Best F.A., and Smith G.N. Prostaglandins in endometrium and menstrual fluid from normal and dysmenorrhoeic subjects. J. Obstet. Gynaecol. Br. Commonw. 72 (1965) 185-192
85. Prentice A. Health care implications of dysfunctional uterine bleeding. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 13 (1999) 181-188
86. Prentice A. Health burden of menstrual disorders. In: O'Brien S., Cameron I., and Maclean A. (Eds). Disorders of the Menstrual Cycle (2000), ACOG Press, London 13-23
87. Rees M.C., Anderson A.B., Demers L.M., and Turnbull A.C. Endometrial and myometrial prostaglandin release during the menstrual cycle in relation to menstrual blood loss. J. Clin. Endocrinol. Metab. 58 (1984) 813-818
88. Rees M.C., Anderson A.B., Demers L.M., and Turnbull A.C. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. Br. J. Obstet. Gynaecol. 91 (1984) 673-680
89. Rees M.C., Canete-Soler R., Lopez Bernal A., and Turnbull A.C. Effect of fenamates on prostaglandin E receptor binding. Lancet 2 (1988) 541-542
90. Rees M.C., and Lopez Bernal A. Effect of inhibitors of prostaglandin synthesis on uterine prostaglandin E receptor binding. Br. J. Obstet. Gynaecol. 96 (1989) 1112-1113
91. Robertson S.A. Seminal plasma and male factor signaling in the female reproductive tract. Cell Tiss. Res. 5 (2005) 1127-1130
92. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., and Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol. Oncol. 76 (2000) 320-325
93. Sales K.J., and Jabbour H.N. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 126 (2003) 559-567
94. Sales K.J., and Jabbour H.N. Cyclooxygenase enzymes and prostaglandins in reproductive tract physiology and pathology. Prostaglandins Other Lipid Mediat. 71 (2003) 97-117
95. 2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J. Clin. Endocrinol. Metab. 86 (2001) 2243-2249
96. Sales K.J., Katz A.A., Howard B., Soeters R.P., Millar R.P., and Jabbour H.N. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, PGE receptors and angiogenic factors by cyclooxygenase-1. Cancer Res. 62 (2002) 424-432
97. 2 receptor expression and signaling in cervical adenocarcinoma cells. Mol. Hum. Reprod. 8 (2002) 1065-1070
98. Sales K.J., List T., Boddy S.C., Williams A.R.W., Anderson R.A., Naor Z., and Jabbour H.N. A novel angiogenic role for Prostaglandin F2a-FP receptor interaction in human endometrial adenocarcinoma. Cancer Research 65 17 (2005) 1-10
99. Sales K.J., Maudsley S., and Jabbour H.N. Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3′,5′-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol. Endocrinol. 18 (2004) 1533-1545
100. 2α receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. J. Clin. Endocrinol. Metab. 89 (2004) 986-993
101. 2 receptor EP2-dependent angiogenesis in APC delta 716 mouse intestinal polyps. Cancer Res. 62 (2002) 506-511
102. Smith S.K. Angiogenesis, vascular endothelial growth factor and the endometrium. Hum. Reprod. Update 4 (1998) 509-519
103. Smith S.K., Abel M.H., Kelly R.W., and Baird D.T. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br. J. Obstet. Gynaecol. 88 (1981) 434-442
104. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
105. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., and Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in APC delta 714 knockout mice. Nat. Med. 7 (2001) 1048-1051
106. Templeton A.A., Cooper I., and Kelly R.W. Prostaglandin concentrations in the semen of fertile men. J. Reprod. Fert. 52 (1978) 147-150
107. 2 receptor. J. Clin. Invest. 103 (1999) 1539-1545
108. 2 in human prostatic carcinoma cells. Br. J. Cancer 75 (1997) 1111-1118
109. 2. Adv. Exp. Med. Biol. 407 (1997) 163-170
110. Tong B.J., Tan I., Tajeda L., Das S.K., Chapman J.A., DuBois R.N., and Dey S.K. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2 (2000) 483-490
111. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., and Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6 (2000) 1024-1028
112. Treloar A.E., Boynton R.E., Behn B.G., and Brown B.W. Variation of the human menstrual cycle through reproductive life. Int. J. Fert. 12 (1967) 77-126
113. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
114. Uotila P.J., Erkkola R.U., and Klemi P.J. The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann. Med. 34 (2002) 428-433
115. Vessey M.P., Villard-Mackintosh L., McPherson K., Coulter A., and Yeates D. The epidemiology of hysterectomy: findings in a large cohort study. Br. J. Obstet. Gynaecol. 99 (1992) 402-407
116. Weston G., and Rogers P.A. Endometrial angiogenesis. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 14 (2000) 919-936
117. Willman E.A., Collins W.P., and Clayton S.G. Studies in the involvement of prostaglandins in uterine symptomatology and pathology. Br. J. Obstet. Gynaecol. 83 (1976) 337-341
118. Wingo P.A., Tong T., and Bolden S. Cancer statistics, 1995. Cancer J. Clin. 45 (1995) 8-30
119. Zervou S., Klentzeris L.D., and Old R.W. Nitric oxide synthase expression and steroid regulation in the uterus of women with menorrhagia. Mol. Hum. Reprod. 5 (1999) 1048-1054